Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia [5]

Leukemia and Lymphoma

Volumn 48, Issue 7, 2007, Pages 1423-1425

  Benson, Don M ^a   Smith, Megan K ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HEMOGLOBIN; IMMUNOGLOBULIN KAPPA CHAIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; VINCRISTINE SULFATE;

ADULT; ANEMIA; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CASE REPORT; CHROMOSOME 13; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; EXERCISE TOLERANCE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HODGKIN DISEASE; HUMAN; IMMUNOPHENOTYPING; INDEPENDENCE; LETTER; LEUKOCYTE COUNT; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PLASMA CELL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK BENEFIT ANALYSIS; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

FEMALE; HUMANS; KINETICS; LEUKEMIA, PLASMACYTIC; MIDDLE AGED; THALIDOMIDE; TREATMENT OUTCOME;

EID: 34447579073     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701361851     Document Type: Letter

References (15)

1. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol, 131, pp. 749-757.
2. Ataergin, S., Arpaci, F., Kaya, A., Turker, K. and Gunhan, O. (2006) VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia. Am J Hematol, 81, pp. 987-988.
3. Blade, J. and Esteve, J. (2000) Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncol, 39, pp. 843-847.
4. Petrucci, M. T., Martini, V., Levi, A., Gallucci, C., Palumbo, G. and Bianco, P Del (2007) Thalidomide does not modify the prognosis of plasma cell leukemia patients: Experience of a single center. Leuk Lymphoma, 48, pp. 180-182.
5. Finnegan, D. P., Kettle, P., Drake, M., Matthews, C., Alexander, H. D. and Popat, R. (2006) Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma, 47, pp. 1670-1673.
6. Grassinger, J., Sudhoff, T., Andressen, R. and Hennemann, B. (2006) Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol, 85, pp. 132-133.
7. Jaskiewicz, A. D., Herrington, J. D. and Wong, L. (2005) Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy, 25, pp. 1820-1825.
8. Esparis-Ogando, A., Alegre, A., Aguado, B., Mateo, G., Gutierrez, B. and Blade, J. (2005) Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer, 114, pp. 665-667.
9. Durie, B GM and Salmon, S. E. (1975) A clinical staging system for multiple myeloma. Cancer, 36, pp. 842-854.
10. Greipp, P. R., Miguel, J San, Durie, B GM, Crowley, J. J., Barlogie, B. and Blade, J. (2005) International staging system for multiple myeloma. J Clin Oncol, 23, pp. 3412-3420.
11. Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E. and McFadden, E. T. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5, pp. 649-655.
12. Anderson, K. C. (2005) Lenalidomide and thalidomide: Mechanisms of action - similarities and differences. Semin Hematol, 4, pp. S3-S8.
13. Richardson, P., Schlossman, R. I., Weller, E., Hideshima, T., Mitsiades, C. and Davies, F. (2002) Immunomodulatory derivative of thalidomide CC5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, pp. 3063-3067.
14. Muller, G., Chen, R., Huang, S. Y., Corral, L. G., Wong, L. M. and Patterson, R. T. (1999) Amino-substituted thalidomide analogs: Potent inhibitors of TNF-production. Bioorg Med Chem Lett, 9, pp. 1625-1630.
15. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G. and Hideshima, T. (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99, pp. 4525-4530.